Based on Bayer’s Grants4Targets goals, established in 2009, the AACR-Bayer Innovation and Discovery Grants will endeavor to develop new treatments, promote originality and efficiency in drug development, and support cooperation between academia and the pharmaceutical industry.
"The AACR is thrilled to partner with Bayer to help transform foundational science into innovative therapeutics for cancer patients," Mitch Stoller, executive director of the AACR Foundation, said. "While we have made great progress against the more than 200 diseases we call cancer, … we must redouble our efforts to provide groundbreaking approaches to treat and prevent cancer."
In April, the Philadelphia-based AACR and Bayer provided two fellowships to cancer researchers. Currently, the program is expected to provide multiple one-year grants between $10,000 and $25,000 whereby recipients will have the option to work with a Bayer mentor.
"Bayer is committed to partnering with elite organizations, and we are delighted to launch the AACR-Bayer Innovation and Discovery Grant program and support exciting early cancer research," Karl Ziegelbauer, Bayer's head of Global Therapeutic Research Groups at Global Drug Discovery, said.
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials.